AUA2025: AUA Advanced Prostate Cancer Course

CME Available: https://auau.auanet.org/node/43035

At the conclusion of this activity, participants will be able to:

1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling.

2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations.

3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC.

4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines.

5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.